Immunoprecise highlights combo neutralization of antibodies

By The Science Advisory Board staff writers

Immunoprecise Antibodies has conducted additional characterization of a subset of fully human, therapeutic SARS-CoV-2 antibodies that are potent and exhibit enhanced neutralization upon combinatorial testing.

Previously, the company demonstrated potent in vitro neutralizing activity of functional antibodies discovered using its DeepDisplay phage technology, B Cell Select, and single-step hybridoma platforms. Now, the company has confirmed that six antibodies covering three epitopes analyzed for enhanced function in combination studies resulted in near complete SARS-CoV-2 pseudovirus infection.

Efforts continue to further analyze multiple additional subsets of antibodies including neutralizing antibodies that bind to the S1 and S2 subunit domains of the SARS-CoV-2 spike protein. The company has begun steps for expression of the lead antibodies for preclinical and clinical manufacturing.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking